Recombinant technology allows engineering and production of proteins with desirable properties. Human serum albumin has been developed with recombinant technology, and thus plays an increasing role as a drug carrier in the clinical setting. Genetic variations usually occur on the surface of the protein, and do not impose significant effects on the conformation of albumin. However, binding of fatty acids by genetic variants is affected according to the location of the mutation. Albumin undergoes three major posttranslational modifications, namely, oxidation, glycation, and S-nitrosylation. This review gives an account of the different posttranslational modifications that should be taken into consideration when designing albumin mutant analogues with desirable pharmaceutical properties.
INTRODUCTION
Human serum albumin (HSA) is a single-chain protein synthesized in and secreted from liver cells. The protein is formed by a single polypeptide chain of 585 amino acids and has a molecular mass of approximately 67000. It is a simple protein without prosthetic groups, glycans, or lipid. It is the most abundant plasma protein, and an important circulating carrier of endogenous and exogenous ligands in the blood. It contributes to the maintenance of osmotic pressure and plasma pH and to the Donnan-effect in the capillaries. 1) Albumin has about 67% alpha-helix but no beta-sheet. Based on X-ray crystallographic analyses of recombinant HSA (rHSA), the polypeptide chain of 585 amino acids forms a heart-shaped protein with dimensions 80ϫ80ϫ80 Å and with a thickness of 30 Å. The analyses also showed that the heart-shaped protein is made up of three homologous domains (I, II, and III), each comprising two subdomains (A and B) with distinct helical folding patterns that are connected by flexible loops. 2) HSA is an important plasma expander. Clinically, HSA is used to treat severe hypoalbuminemia or traumatic shock, and the usual dosages of HSA are in excess of 10 g/dose. To date, albumin has been produced by fractionation of whole blood. However, the potential risk of HSA contamination with blood-derived pathogens has prompted the development of an alternative method of industrial production of HSA. Recombinant HSA expressed by Pichia pastoris is commercially available. 3, 4) The clinical safety and efficacy of HSA administration to critically ill patients have been debated due to the heterogeneity and oxidation status of commercial HSA preparations. Significant differences in posttranslational modifications exist among the various commercial preparations of albumin. Administration of such products to critically ill patients might elicit undesirable immune responses. 5, 6) In regard to this potential risk, recombinant HSA may be less problematic than plasma-derived human albumin. 7) Further to improve the stability of HSA products, stabilizers such as N-acetyl-tryptophan and N-acetyl-methioninate which have protective effect on thiol group, can be included. 8, 9) In addition, Anraku et al. 10) found that chitosan is as effective as vitamin C in preventing formation of carbonyl and hydroperoxide groups in HSA exposed to peroxyl radicals. Co-administration of low-molecular weight chitosans may inhibit neutrophil activation and oxidation of HSA commonly seen in patients undergoing hemodialysis (HD), resulting in reduction of uremia related oxidative stress.
The half-life of HSA in humans is 19 d. From a clinical point of view, it would be beneficial if the protein could be engineered to have a longer half-life in the circulation. In addition, its ease of synthesis and its known structure has made albumin an attractive candidate for use in recombinant fusion proteins for the purpose of extending the half-life of small proteins that would otherwise be rapidly cleared. [11] [12] [13] [14] [15] HSA is known to undergo various modifications upon secretion into the general circulation, with oxidation, glycation, and nitrosylation being the three main posttranslational modifications. Despite multiple reports on its clinical use and application possibilities as a drug carrier, not much has been done to clarify the effects of posttranslational modifications on the pharmaceutically desirable properties of HSA.
EFFECT OF GENETIC VARIATION ON HSA
Genetic Variants There are 77 genetic variants of human albumin compiled by Peters.
16) Twenty-two genetic variants were found in domain I, 30 in domain II, and 25 in domain III (Table 1 ; Fig. 1 ). 16) Most of the mutations are benign; a total of 65 mutations result in bisalbuminemia. 17) The effect of genetic variation on the thermal stability of HSA was studied at our laboratories. Reversible thermal denaturation of 33 genetic variants of HSA appeared to be a two-state process when studied by circular dichroism. For all variants, no clear relationship was found between the changes in the thermodynamic parameters and the type of substitution, changes in protein charge, and hydrophobicity. However, the protein changes taking place in domain I have a rather uniform effect; they denature more easily than normal albumin but they do so at a higher temperature. 18) Changes in hydrophobicity and net charge on the surface of albumin as a result of chemical modification are known to affect its in vivo clearance. 19, 20) Screening of HSA genetic variants identified so far with structural characterization has been made by Iwao et al. 21) Seventeen structurally different genetic variants of HSA with single-residue mutations isolated from heterozygote carriers have been selected for pharmacokinetic studies in mice. In all cases, the plasma half-life was affected but only variants with ϩ2 changes in charge prolonged it, whereas changes in hydrophobicity decreased it. Good positive and negative correlations were found between changes in alpha-helical content taking place in domains IϩIII and domain II, respectively, and changes in halflives. 21) Very recently, we reported the plasma half-lives and organ uptakes of these HSAs with slightly longer chainlength (proalbumin variants), three with a slightly shorter length (C-terminal variants), and three alloalbumin N-glycosylated in domains I, II, and III, respectively. No correlation was found between mutation-induced changes in the pharmacokinetic parameters and changes in alpha-helical content or changes in heat stability. 22) Nakajou et al. 23) showed that the clearance of a recombinant triple-residue mutant (K199A/ K439A/K525A) is faster than that of the wild-type rHSA, confirming the influence of positive charges of lysine at positions 199, 439, and 525 of human albumin.
The plasma half-life of HSA can also be modified by single-residue modification. The clearance of six recombinant single-residue mutants (H146A, K199A, W214A, R218H, R410A, Y411A) was analyzed in mice. No significant change in the pharmacokinetics and structural properties was observed for the W214A, R218H, and Y411A mutants. In contrast, H146A, K199A, and R410A mutants exhibited different properties (extent of mutation effect: R410AϾK199AϾ H146A). Liver clearance of these proteins appeared closely correlated to hydrophobicity and the net charge of the proteins.
24)
Glycosylated Variant A double-mutant albumin, Red- However, a minor part (11 mol%) of the glycan was without sialic acid. The structure is principally the same as that of glycans bound to two other types of glycosylated albumin variants. Glycosylation can affect the fatty acid-binding properties of albumin. Taking the present information into account, it is apparent that different effects on binding are caused not by different glycan structures but by different locations of attachment, with the possible addition of local conformational changes in the protein molecule. 25) Albumin Kenitra is peculiar because it has an elongated polypeptide chain, 601 residues instead of 585, and its sequence is modified beginning from residue 575. The four additional cysteine residues of the variant form two new S-S bridges and showed that albumin Kenitra is partially O-glycosylated by a monosialylated HexHexNAc structure. This oligosaccharide chain has been located to Thr596. 26, 27) Kinetic dialysis studies of laurate binding at physiological pH showed that the binding constant of glycosylated Alb Casebrook (modified in domain III) was decreased to 20%. Binding to the glycosylated Alb Redhill (modified in domain II) was also decreased, but to a smaller extent (68%). These decreases in binding are caused by partial or total blocking of the high-affinity site by the oligosaccharides, by the negative charges of the oligosaccharides, and/or by conformational changes induced by these bulky moieties.
27)
Fatty Acid Binding One of HSA's principal functions is to transport fatty acids. In the circulation, non-esterified fatty acids are transported by albumin, which also facilitates their removal from donor cells and uptake into receptor cells. The primary association constants increased, but not linearly, with chain length. The number of high-affinity sites also increased with chain length; octanoate and decanoate bind to one such site, whereas laurate and myristate most probably bind to two sites. Amino acid substitutions of genetic albumin variants (alloalbumins) are situated at the surface of the protein; usually these substitutions have no effect on fatty acid binding. 28) Mutations in domains I and II and the propeptide resulted in smaller effects, if any, and these were often reductions in binding. High-affinity binding of laurate to naturally occurring mutants of human serum albumin and proalbumin showed that the first stoichiometric association constant for binding to proalbumin Lille (Arg-2→His) and albumin (Alb) Roma (Glu321→Lys) was increased to 126% and 136%, respectively, compared with that for binding to normal albumin. Albumin Brest (Asp314→Val) has improved in vivo fatty acid-binding properties, whereas the structural modification(s) of albumin Ildut (Arg-2→Cys) does not affect fatty acid binding. 29) The most pronounced changes and the majority of cases of increased binding were caused by molecular changes in domain III. While the fatty acid binding properties of a proalbumin variant Zagreb (-1Arg→Gln) are normal, albumin Krapina with amino acid substitution in position 573 resulted in a general decrease of fatty acid binding. 30) The binding constant of laurate for Alb Maku (Lys541→Glu) was decreased to 80%. Laurate binding to two chain-termination mutants (Alb Catania and Alb Venezia) was normal, indicating that the C-terminus of albumin is not important for binding. 27) Among the three variants detected in Italy that are caused by single point mutations, Trieste, (Lys359→Asn), Milano Slow (Asp375→His), and Liprizzi (Arg410→Cys), albumins Trieste and Milano Slow have mutations involving residues on the surface of the molecule. In contrast, albumin Liprizzi represents the first example of a mutation in the most active binding pocket of the molecule, placed in subdomain IIIA. 31) Thirteen recombinant isoforms mutated in four different subdomains were synthesized to study the binding of octanoate, decanoate, laurate, and myristate by a rate-of-dialysis technique. The results showed that octanoate and decanoate bind to a single site in subdomain IIIA; laurate binds to sites in subdomains IIIA and IIIB, whereas myristate binds in subdomains IB and IIIB. The results also showed that primary fatty acid binding is sensitive to amino acid substitutions in other parts of the protein. 32) The association constants for Ni 2ϩ decreased by more than one order of magnitude in proalbumin (proAlb) Varese (Arg2→His), proAlb Christchurch (Arg-1→Gln) and proAlb Blenheim (Asp1→Val) and by the presence of only an extra Arg residue (Arg-1) as in Arg-Alb and albumin (Alb) Redhill. The modification of Alb Blenheim (Asp1 Val) reduces the binding constant to 50%. This could be explained by the ion binds to a site in the N-terminal region of the protein, which is partially blocked by the presence of a propeptide. Ca 2ϩ binding is decreased to about 60-80% by the presence of a propeptide and the mutation Asp1→Val. Arg-1 alone does not affect binding. In contrast, Alb Redhill binds Ca 2ϩ more strongly than the normal protein (125%). The binding constant for Zn 2ϩ is increased to 125% in the case of proAlb Varese, decreased to 50-60% for proAlb Christchurch and Alb Redhill, and is normal for proAlb Blenheim, Alb Blenheim, and Arg-Alb. 33) High-affinity binding of progesterone, testosterone, prostaglandin F 2 alpha, and L-thyroxine to five genetic variants of human serum albumin with defined point mutations was investigated by equilibrium dialysis (pH 7.4). Variants Albumin Niigata (Asp269→Gly), Albumin Roma (Glu321→Lys), Albumin Parklands (Asp365→His), and Albumin Verona (Glu570→Lys) all had normal progesterone-binding properties whereas Albumin Canterbury (Lys313→Asn) was 1.5 times that calculated for binding to the corresponding endogenous albumin. Specificity with respect to the type of mutation was also found for the binding of testosterone and prostaglandin F 2 alpha. Testosterone binding to Albumin Roma was only 0.7 of that determined for endogenous albumin, whereas prostaglandin F 2 alpha binding to Albumin Niigata was increased by a factor 2.4. On the other hand, normal binding properties were found for all the variants in the case of L-thyroxine. 34) 
POSTTRANSLATIONAL MODIFICATION OF ALBUMIN
Oxidation Free raicals are a normal component of cellular oxygen metabolism in mammals. However, free radicalassociated damage is an important factor in many pathological processes. Oxidative posttranslational modifications of plasma proteins may serve as hallmarks of disease severity and could result in altered protein function and structure. Oxidation of HSA is also age related where in the elderly it becomes more oxidized than in young subjects. 35) Mild oxidation of HSA has no detectable effect on the binding of drugs to site I in subdomain IIA. In contrast, the ligand-binding property of site II and the esterase-like activity of oxidized HSA are decreased, most probably due to conformational changes in subdomain IIIA. 36) Liver and spleen uptake clearance of oxidized HSA were significantly greater than those of normal HSA. 37) Oxidation of key amino acid residues such as R410 may promote the elimination of HSA. 24) HSA has 35 cysteine residues. All of these cysteine residues except Cys34 are involved in the formation of stabilizing disulfide bonds. Cys34 in domain I of albumin is the binding site for a wide variety of biologically and clinically important small molecules. It provides antioxidant activity and constitutes the largest portion of free thiol in blood. 38) In patients with acute lung injury or sepsis syndrome, albumin administration favorably influences plasma thiol-dependent antioxidant status as well as levels of protein oxidative damage. 39, 40) Bourdon et al. 41) found that Met and Cys accounted for 40-80% of total antioxidant activity of HSA. They concluded that Cys chiefly works as a free radical scavenger whereas Met mainly acts as a metal chelator. 41) Their findings have been confirmed by our laboratory in a study using single-residue mutant (Cys34A) and six-residue mutant (M87A/ M123A/M298A/M329A/M446A/M548A) forms (unpublished data). The major structural change in oxidized HSA in healthy human plasma is a disulfide-bonded cysteine at the thiol of Cys34 of reduced HSA. 42) Oxidation of lysine residues leads to the formation of 2-aminoadipic semi-aldehyde residues. Under metal-catalyzed oxidation conditions, only two of the 59 lysine residues of HSA appeared modified (Lys-97 and Lys-186). On the other hand, five different lysine modification sites were identified (Lys-130, Lys-257, Lys-438, Lys-500, and Lys-598) in hypochlorous acid treatment, suggesting that the preferred site of modification is dependent on the nature of the oxidant and that the process relies on specific structural motifs in the protein to direct the oxidation (Fig. 2) . 43) Pulmonary hypertension in sickle cell anemia is characterized by decreased nitric oxide bioavailability that might, in part, be related to oxidative stress. Amino acid residue K159 of albumin has been demonstrated a site of malondialdehyde modification that was differentially present in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension in sickle cell anemia. 44) HSA exists in both reduced and oxidized forms, and the percentage of oxidized albumin increases in several diseases. An increased level of oxidized HSA may impair HSA function in a number of pathological conditions. 42, 45) Oxidative stress is believed to play an important role in the pathogenesis of liver failure. The serum albumin level is related to prognosis in advanced liver disease. Progressive oxidative modification of albumin was found with increasing severity of liver failure indicated by an increased content of carbonyl groups and oxidation of cysteine-34, with a preferred binding 530 Vol. 32, No. 4
Fig. 2. Oxidation Sites of Human Serum Albumin (HSA)
Cysteine 34 is particularly susceptible to oxidation, and also the site for S-nitrosylation.
of bilirubin to the fully reduced form of albumin in patients with acute-on-chronic liver failure. 46) Oxidative stress was enhanced in correlation with the level of renal dysfunction among patients with chronic renal failure. 47) Plasma albumin has been found to undergo massive oxidation in primary nephrotic syndrome. 48) Oxidized albumin is a reliable marker of oxidative stress in HD patients because albumin is the major plasma protein target of oxidant stress in chronic renal failure and HD patients. 49 ) An increase in plasma protein carbonyl levels in HD patients was largely due to an increase in oxidized albumin. HD-HSA was found to have a lower antioxidant activity than normal HSA. HD-HSA was also able to trigger the oxidative burst of human neutrophils. Uremia plays an important role in the progression of oxidative stress in HD patients because uremic toxins may possibly play a role in mediating free radical-initiated protein damage. 50) Diabetic complications exacerbate the condition by further increasing the amount of oxidized HSA molecules. 51, 52) End-stage renal disease is associated with enhanced oxidative stress and may contribute to substantial cardiovascular complications in HD patients. The quality and integrity of HSA molecule in HD patients have been shown subtly altered and as a result HSA's biological properties are impaired. Intravenous iron administration, which is effective for correcting anemia in HD patients, enhances generation of hydroxyl radicals and thus oxidation of albumin in those patients. 53, 54) Oxidative alterations of this major plasma protein might adversely affect its vasculoprotective effects in HD patients. Hence antioxidant strategies should become part of treatment for predialysis renal failure.
55)
Non-enzymatic Glycation Structural modification of protein by carbohydrate falls into two broad categories: nonenzymatic glycation, which refers to the attachment of free carbohydrate to proteins in the Amadori construct, and advanced glycation endproducts (AGE), which refers to a heterogeneous group of carbohydrate-modified products generated from the Amadori adduct by oxidation, polymerization, and other spontaneous reactions. 56) Nonenzymatic glycation is one of the underlying factors contributing to the development of complications of diabetes. HSA is nonenzymatically glycated by reducing sugars in the general circulation. The reference range of glycated albumin in normal humans is 6-10%. However, this proportion typically increases to between 20% and 30% in hyperglycemic patients.
Arg-410 was found to be a hotspot of modification by methylglyoxal in albumin glycated in vivo. Other sites of minor modification were: Arg-114, Lys-186, Arg-218, and Arg-428 (Fig. 3) . 57) On the other hand, the other principal site of glycation on HSA is Lys-525, but the lysine residues in positions 199, 281, and 439 are also susceptible to glycation. AGE formation of HSA is associated with extensive damage to histidine and tryptophan side chains, main chain fragmentation, and loss of both secondary and tertiary structure as a result of oxidation. 58) In structural analysis, the increases in advanced oxidation protein products and dityrosine content of HSA induced slight decreases in its alpha-helical content. 37) Using mesangial cells from SR-A knockout mice Nakajou's group 59, 60) showed that a class A scavenger receptor, SR-A, contributes approximately 40% to the binding and approximately 80% to the subsequent degradation of AGEmodified proteins. This pathway may contribute to the pathogenesis of AGE-induced diabetic nephropathy (Fig. 4) . The advanced oxidation protein products have been shown involved in the development of renal fibrosis via the CD36 pathway. 61) Free radical production is increased during diabetes. Glycation and oxidative damage cause protein modifications, as can be frequently observed in numerous diseases. Albumin is a major and important circulating antioxidant. 62) Structural modification of albumin induced by glucose or free radicals impairs its antioxidant properties. 63) HSA of type 1 diabetes mellitus patients is conformationally altered, with more exposure of its hydrophobic regions. In addition, hydroxyl radical modified HSA was found highly immunogenic in rabbits as compared with native HSA. Sera from elderly type 1 diabetes mellitus patients having smoking history, and advanced disease showed substantially stronger binding to hydroxyl radical-modified HSA over normal HSA. These findings suggest that oxidation of plasma proteins, especially HSA, might enhance oxidative stress in type 1 diabetes mellitus patients. 64 ) Serum albumin of type 2 diabetes mellitus patients has decreased antioxidant properties that may aggravate oxidative stress. 65) Similarly decreased antioxidant activity of serum albumin can be found in obstructive sleep apnea patients.
66)
S-Nitrosylation Nitric oxide (NO) is a short-lived physi- ological messenger. Its various biological activities can be preserved in a more stable form of S-nitrosothiols.
67) The Snitrosylated forms of certain proteins such as albumin have been thought to be circulating endogenous reservoirs of NO and may have potential as NO donors in therapeutic applications. 68, 69) In addition to serving as a reservoir for NO, Snitrosothiols themselves have various biological activities, possibly through transnitrosylation, S-thiolation, and direct action of other biological molecules. 70, 71) Many potential clinical uses for S-nitrosothiols have been suggested such as its potential use as a therapeutic agent.
72)
S-Nitroso HSA acts primarily as a venodilator in vivo and represents a stable reservoir of NO that can release NO when the concentrations of low-molecular-weight thiols are elevated.
73) S-Nitroso HSA has been shown to reduce ischemia or reperfusion injury in the pig heart after unprotected warm ischemia through long-lasting release of NO. This prevents uncoupling of endothelial NO synthase, which is a major contributor to vascular reactive oxygen species generation in ischemia and reperfusion injury, and thereby improves systolic and diastolic function, myocardial perfusion, and the energetic reserve of the heart after such insults. 74 ) Similar cardioprotective effect on rabbit has also been reported. 75) In a recent study, S-nitrosylated HSA was shown to have antitumor activity through apoptosis induction without causing hepatic or renal damage. This suggests that NO-HSA has chemopreventive and/or chemotherapeutic activity with few side effects. 76) Ishima et al. 77) showed in a rat ischemia/reperfusion model that binding of oleate to S-nitrosylated HSA enhances its cytoprotective effect on liver cells. Addition of oleate increased the accessibility of the single thiol group of albumin and improved S-denitrosation of SNO-HSA by HepG2 cells. It enhances the antiapoptotic effect of SNO-HSA on HepG2 cells exposed to anti-Fas antibody. This may lead to preparation of an S-nitrosylated HSA dosage form that will produce better treatment outcome. 77) 
DESIGN OF ALBUMIN MUTANT ANALOGUES WITH DESIRABLE PHARMACEUTICAL PROPERTIES
Extended Half-Life Albumin Analogue Oxidation promotes elimination of albumin. 24) It is therefore tempting to design an oxidation-resistant albumin analogue that has a prolonged half-life. Nevertheless, the antioxidant property of albumin helps to improve the conditions of critically ill patients. One possible approach is genetically to fuse two molecules of human albumin to produce a recombinant albumin dimer. This will allow the desired antioxidant property to be sustained in the dimer.
Dimerization of human albumin has been reported to extend the half-life by approximately 1.5 times greater than that of the wild-type HSA monomer. Dimerization also causes a significant decrease in the total body clearance and distribution volume at steady state of HSA. In addition, rHSA dimer also has a high retention rate in circulating blood and a lower vascular permeability than normal HSA. This dimer has good potential for use in critically ill patients with hypovolemia, burns, and hypoalbuminemia. 78) The MHC class I-related neonatal Fc receptor (FcRn) has been reported to serve in the homeostatic regulation of IgG and albumin by increasing their half-lives. Elucidation of the FcRn-albumin interaction will shed light on a more sophisticated design of albumin analogue with long half-life without compromising its antioxidant property. 79) Antibacterial Albumin Analogue Albumin Liprizzi is a genetic variant of HSA detected in Italy that represents the first example of a mutation in the most active binding pocket of the molecule, Arg410→Cys, placed in subdomain IIIA. 31) S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial activity against Salmonella typhimurium in vitro and cytoprotective properties via suppressing apoptosis of U937 human promonocytic cells induced by Fas ligand. S-Nitrosylated R410C treatment of ischemia-reperfusion liver injury in a rat model significantly reduced liver damage. 80) The increased cytoprotective effect appears enhanced by fatty acid binding. 77) Iwao et al. 24) reported that a single amino acid substitution at position 410 from arginine to alanine (R410A) shortened the half-life of the HSA mutant in circulation. Interestingly, S-nitrosylation of R410C prolonged its half-life in circulation, probably through reduced liver uptake. Based on these advantages, further investigation of the use of S-nitrosylation R410C albumin in clinical settings is warranted.
Oxidation-Resistant Albumin Analogue
The accumulation of albumin-bound toxins such as bilirubin in liver failure is believed responsible for the development of associated end-organ dysfunctions. Albumin-bound toxins are also important in the pathophysiology of systemic inflammatory response syndrome, and poisoning. Due to its intrinsic ability to bind molecules, albumin has been used in blood purification techniques such as single-pass albumin dialysis, 81, 82) the molecular adsorbent recirculating system, 83, 84) and the Prometheus systems. 85, 86) The molecular adsorbent recirculating system of albumin dialysis is a high-flux dialysis setting using HSA as a molecular adsorbent to the dialysate with subsequent recirculation of the dialysate over sorbents. It is a useful tool to treat acute liver failure and decompensated chronic liver disease, and to provide a bridge for patients to liver transplantation. 83, 87) Since oxidation of albumin compromises its ligand-binding property and shortens its shelf life, it is logical to use an oxidation-resistant albumin analogue for the purpose of albumin dialysis. Oxidation resistance could be conferred to an albumin molecule through mutation of cysteine or methionine residues that are susceptible to free radical attack. However, it is of interest to investigate whether antioxidant property of albumin is desirable for facilitating radical species removal in albumin dialysis. 88) Komatsu and coworkers [89] [90] [91] genetically engineered heme pocket on recombinant HSA for complexation of iron protoporphyrin IX to generate an artificial hemoprotein, which was effective in binding oxygen in much the same way as hemoglobin (Hb). Although the pharmacokinetic profile of this albumin-heme is yet to be investigated, it is possible that the bound oxygen may reduce the half-life of albumin through preferential oxidation. Hence another potential use of oxidation-resistant albumin analogue is in the production of albumin-heme complex.
High Toxin-Capturing Albumin Analogue Bilirubin and uremic toxins, endogenous substances that cause jaundice, are difficult to remove from blood by conventional HD because most toxins including bilirubin are water-insoluble and bind albumin with high affinities. Recently, molecular adsorbent recirculating system (MARS), which utilizes dialysis solution containing HSA, has been developed for removal of toxins such as bilirubin and furan dicarboxylic acid. However, this system needs to overcome a problem in that bilirubin also binds to other components of blood. This system's shortcoming can be overcome by developing an albumin analogue that binds bilirubin with higher affinity than other plasma proteins. In addition, this high toxin-capturing albumin analogue may also benefit from oxidation-resistant property for use in dialysis solution of MARS (Fig. 5) .
CONCLUSION
It appears that albumin is playing an increasing role as a drug carrier in clinical settings. However, the design of human albumin mutant analogues with desirable pharmaceutical properties can be a difficult and mammoth task because the protein undergoes multiple posttranslational modifications. With clarification of the effect of each posttranslational modification onto the protein molecule, an albumin analogue might be designed for a specific application. This "old but new plasma protein" has great potential for various applications than ever expected. 
